The paper's citation list
No. | The paper's citation list |
|---|
1 | FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis. 2024;24:1501 doi: 10.2174/0118715206345788240902062910 |
2 | A Beginner's Guide to Targeted Cancer Treatments and Cancer Immunotherapy. 2025;109 doi: 10.1002/9781119834090.ch3 |
3 | Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments. 2024;36:569 doi: 10.1097/CCO.0000000000001094 |
4 | Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect. 2023;102:3025 doi: 10.1007/s00277-023-05392-2 |
5 | Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. 2024;84:905 doi: 10.1158/0008-5472.CAN-23-1534 |
6 | Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia. 2025;160:108424 doi: 10.1016/j.bioorg.2025.108424 |
7 | AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens. 2023;24:15849 doi: 10.3390/ijms242115849 |
8 | RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives. 2024;14: doi: 10.1038/s41408-024-01054-2 |
9 | Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia. 2024;25:9448 doi: 10.3390/ijms25179448 |
10 | Gene Mutation Characteristics and Prognostic Significance in Acute Myeloid Leukemia Patients From Northeast China. 2025;2025: doi: 10.1155/humu/7730186 |
11 | Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups. 2024;16:4028 doi: 10.3390/cancers16234028 |
